Left atrial appendage occlusion: Initial experience with the Amplatzer™ Amulet™

Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet

“…These series with 17 [7], 20 [8], 24 [9] and 50 [10] patients reported 100%, 100%, 96% and 94% procedural process. The Amulet observational study with 1,073 patients reported 98.8% implant success [14].…”

“…First series of LAAO with the Amplatzer Amulet showed similar procedural and short-term clinical outcomes compared with the ACP [7][8][9][10]. In the series of Abualsaud et al [11] with 50 patients the Amulet was associated with a significant reduction in residual leaks at follow-up.…”

Device‐associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet

“…Overall, complete thrombus resolution under treatment was achieved in the vast majority of cases (95.0%, 38/40 cases). Partial resolution was also reported in rare cases (2/40 cases) but late FU data was not available in these cases . Recurrence rate was low with only two reported cases at one and 3 months after cessation of intensified antithrombotic regimen but the number and duration of imaging FU after thrombus resolution are unknown .…”

“…Treatment duration varied greatly with reported minimal duration of 2 weeks and maximum duration to 6 months or even long‐term anticoagulation in two cases [1 case with long‐term OAC , 1 case with long‐term dalteparin ]. The median duration of antithrombotic treatment in our analysis was 45 days (IQR: 14–135), with shorter treatment duration for LMWH [14.0 days (IQR: 14.0–14.0)] compared to OAC [90.0 days (IQR: 90.0–180.0)], P ≤ 0.0001.…”

Left Atrial Appendage Occlusion: What Are the Options and Where is the Evidence?

“…The WATCHMAN™ (Boston Scientific, Natick, MA, USA) and the AMPLATZER™ Amulet™ (Abbott Laboratories, Chicago, IL, USA)-the latter of which gained CE mark approval in January 2013 but which is still part of a clinical trial in the United States-are two devices proven to be effective in this approach. [10][11][12][13] A third device, the percutaneous LAA transcatheter occlusion (PLAATO) system (Appriva Medical Inc., Sunnyvale, CA, USA), was previously tested but was discontinued in 2006.…”